Key Takeaway: Vor Bio has reported its second quarter 2026 financial results, highlighting that enrollment is on track for the Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis. Additionally, enrollment is ongoing for the Phase 3 UPSTREAM trial in primary Sjögren’s disease. The company also noted a robust cash and investment balance of $514.5 million.
Market Sentiment Analysis
POSITIVE FACTORS
Enrollment on track for Phase 3 trials.
Topline results for UPSTREAM MG trial expected in 1H27.
Strong cash and investment balance of $514.5 million.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+442%
120-day peak, hindsight
Typical move
18.8%
average across 6 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
Telitacicept
Phase 3 · Primary Sjogren's Disease
Full Press Release Details
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren’s disease Pro-forma cash and investment balance of $514.5 million
Frequently Asked Questions
What are the key updates from Vor Bio's Q2 2026 report?
Vor Bio reported enrollment progress for Phase 3 trials and a strong cash balance.
What is the expected timeline for the UPSTREAM MG trial results?
Topline results for the UPSTREAM MG trial are anticipated in the first half of 2027.
How much cash does Vor Bio currently have?
Vor Bio has a pro-forma cash and investment balance of $514.5 million.
What diseases are being targeted in Vor Bio's trials?
The trials target generalized myasthenia gravis and primary Sjögren’s disease.